Trial Profile
A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary) ; Clopidogrel
- Indications Pulmonary embolism; Stroke
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 27 Feb 2020 Results evaluating the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects published in the Journal of Clinical Pharmacology
- 18 Mar 2017 Results evaluating safety and pharmacokinetics of DS-1040 in combination with Clopidogrel, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 16 Jun 2016 Status changed from recruiting to completed.